Semaglutide vs Retatrutide
Head-to-head comparison of Semaglutide and Retatrutide for research applications. Both peptides are studied for Weight Management and Metabolic Health, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Semaglutide | Retatrutide |
|---|---|---|
| Category | Metabolic / GLP-1 Agonist | Metabolic / Triple Agonist |
| Mechanism | Semaglutide mimics the GLP-1 hormone by binding to GLP-1 receptors on pancreatic beta cells (glucose-dependent), brain (hypothalamus appetite centers), stomach, and intestines. | Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon... |
| Evidence Rating | A — FDA Approved | B — Phase III / NDA Filed |
| Clinical Status | FDA-approved (Ozempic for T2D, Wegovy for obesity) | Phase 3 clinical trials (Eli Lilly TRIUMPH program) |
| Safety Profile | Common (5%+ in trials): nausea, vomiting, diarrhea, abdominal pain, constipation (usually dose-dependent and transient); Additional common effects: upset stomach, heartburn, burping, gas, bloating, loss of appetite, headache, dizziness, tiredness | GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate; GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) |
| Route | Subcutaneous (weekly injection); Oral tablet available (Rybelsus) | Subcutaneous (clinical trial formulation only) |
| Dose Range | SC: 0.25–2.4 mg/week titrated over 16 weeks; Oral: 3–14 mg/day | Phase 2 tested 1, 4, 8, 12 mg weekly SC; optimal dose being determined in Phase 3 |
| Frequency | Once weekly (SC); Once daily (oral) | Once weekly |
| Molecular Weight | ~4113.6 g/mol | N/A |
| Half-Life | ~160–168 hours (~7 days) | ~6 days (allows once-weekly dosing) |
Overview
Semaglutide and Retatrutide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Semaglutide — Mechanism & Evidence
Semaglutide is an FDA-approved GLP-1 receptor agonist (MW ~4113.6 g/mol, molecular formula C187H291N45O59) with 94% sequence homology to human GLP-1. It is approved for type 2 diabetes (Ozempic), chronic weight management (Wegovy), and non-cirrhotic MASH (Wegovy). Developed by Novo Nordisk and first FDA-approved December 5, 2017, it is backed by the extensive STEP and SUSTAIN trial programs involving thousands of patients. There is no generic semaglutide available, and the FDA has warned about counterfeit products.
Key claims: Causes significant weight loss; Improves blood sugar control; Reduces cardiovascular risk.
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
Semaglutide 10mg
10mg
Retatrutide — Mechanism & Evidence
Retatrutide is a first-in-class investigational triple hormone receptor agonist (GIP, GLP-1, and glucagon) developed by Eli Lilly. In the Phase 2 trial (Jastreboff et al., NEJM 2023, n=338), the 12 mg dose achieved 24.2% mean body weight reduction at 48 weeks, with 100% of participants achieving at least 5% weight loss. Multiple Phase 3 TRIUMPH trials are ongoing, with TRIUMPH-4 (Dec 2025) reporting average loss up to 71.2 lbs with osteoarthritis pain relief. Expected FDA approval is 2027-2028.
Key claims: Unprecedented weight loss in Phase 2; Phase 3 confirms efficacy with osteoarthritis benefit; Improves glycemic control in type 2 diabetes.
Shared Research Applications
Both peptides are studied for: Weight Management, Metabolic Health.
Semaglutide is also researched for: Cardiovascular.
Retatrutide is also researched for: no additional unique applications.
Safety Considerations
Semaglutide: Common (5%+ in trials): nausea, vomiting, diarrhea, abdominal pain, constipation (usually dose-dependent and transient) Additional common effects: upset stomach, heartburn, burping, gas, bloating, loss of appetite, headache, dizziness, tiredness Serious but rare: pancreatitis, gallbladder disease, severe allergic reactions (hives, swelling, difficulty breathing)
Retatrutide: GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) Dose-dependent heart rate increases peaking at 24 weeks, declining thereafter
Shop Research Peptides
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
Semaglutide 10mg
10mg
BPC-157 5mg
5mg
Ipamorelin 10mg
10mg
TB-500 5mg
5mg
GHK-Cu 50mg
50mg
Sermorelin 5mg
5mg
Tesamorelin 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Lilly Beats Estimates as Injectable GLP-1 Demand Stays Strong: Semaglutide News
Eli Lilly exceeded earnings expectations on resilient demand for injectable GLP-1 therapies. As the field looks toward upcoming conferences, semaglutide news and next-gen peptides like retatrutide are shaping the anti-obesity landscape.
Retatrutide in Canada: Access, Trials, and Approval Timing
Retatrutide is not yet approved in Canada; access is limited to clinical trials. This article outlines the current status, evidence, and realistic timelines for availability.
Tirzepatide vs Retatrutide: Evidence, Mechanisms, Safety
This reference distinguishes randomized trial evidence from extrapolation for tirzepatide and retatrutide, clarifying mechanisms and safety. It highlights the absence of direct head-to-head trials and the limits of current data.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe